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Abstract
Background: Cytomegaloviruses (CMVs) are herpesviruses that infect many mammalian species, including humans.
Infection generally passes undetected, but the virus can cause serious disease in individuals with impaired immune
function. Human CMV (HCMV) is circulating with high seroprevalence (60–100 %) on all continents. However, little
information is available on HCMV genoprevalence and genetic diversity in subsaharan Africa, especially in rural
areas of West Africa that are at high risk of human-to-human HCMV transmission. In addition, there is a potential for
zoonotic spillover of pathogens through bushmeat hunting and handling in these areas as shown for various
retroviruses. Although HCMV and nonhuman CMVs are regarded as species-specific, potential human infection with
CMVs of non-human primate (NHP) origin, shown to circulate in the local NHP population, has not been studied.
Findings: Analysis of 657 human oral swabs and fecal samples collected from 518 individuals living in 8 villages of
Côte d’Ivoire with generic PCR for identification of human and NHP CMVs revealed shedding of HCMV in 2.5 % of
the individuals. Determination of glycoprotein B sequences showed identity with strains Towne, AD169 and Toledo,
respectively. NHP CMV sequences were not detected.
Conclusions: HCMV is actively circulating in a proportion of the rural Côte d’Ivoire human population with
circulating strains being closely related to those previously identified in non-African countries. The lack of NHP
CMVs in human populations in an environment conducive to cross-species infection supports zoonotic transmission
of CMVs to humans being at most a rare event.
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Findings
Human cytomegalovirus (HCMV) is a ubiquitous her-
pesvirus (subfamily Betaherpesvirinae) that infects the
majority of the human population by early adulthood
[1]. Although generally benign in healthy individuals,
HCMV can cause serious disease in the absence of com-
petent immune function, such as occurs in newborns,
non-HAART treated AIDS patients and transplant recip-
ients undergoing iatrogenic immunosuppression [2–4].
Similar to all herpesviruses, acute infection by HCMV
and nonhuman CMV is followed by establishment of a
persistent/latent infection for the lifespan of the host,
with periodic reactivation and shedding. Superinfection
of HCMV seropositive individuals is also possible, result-
ing in the frequent circulation of multiple HCMV strains
within the population. Although regarded as highly
species-specific, the capacity for zoonotic transmission
of nonhuman CMV from closely related nonhuman pri-
mate (NHP) wildlife species remains an important, but
unexplored question. HCMV sero- and genoprevalence
and strain sequences have been determined in several
countries world-wide (e.g. [5–11]), but little informa-
tion is available from subsaharan Africa [12–18], espe-
cially on CMV nucleotide sequences in rural areas of
West Africa that are at high risk of human-to-human
HCMV transmission and are zoonotic ‘hot-spot’
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regions due to behaviors such as bush-meat hunting
and slaughtering [19–21].
A landmark study by Jones et al. [22] has identified
emerging infectious disease (EID) ‘hotspots’ within
poorer regions of West Africa, South America and Asia
that are most frequently associated with zoonotic emer-
gence of pathogens with global health significance. In
the present study, human subjects in rural Côte d’Ivoire
living in villages surrounding the Taï Forest National
Park were analyzed for shedding of HCMV and NHP
CMVs. NHPs are a primary source of zoonotic disease
[23–27] and wildlife including monkeys represents an
important component of diet (“bush meat”) in rural Côte
d’Ivoire [28–30]. A recent study has shown a consider-
able incidence of CMV in colobus monkeys from this
geographic region, 10 % in black-and-white colobus and
22 % in western red colobus [31]. This rural human
study group therefore represented a population with po-
tentially high exposure to NHPs carrying and excreting
NHP CMVs. We reasoned that focusing on the identifi-
cation and characterization of CMVs within those indi-
viduals actively shedding CMV within this large human
study population would provide a sensitive means by
which to assess on the one hand the circulating HCMV
strains and on the other hand the propensity for zoo-
notic transmission of NHP CMVs.
As part of a larger study investigating human contact
to animal viruses through bush meat hunting, prepar-
ation and consumption [32–34], 657 samples (472 oral
swabs and 185 fecal samples) from 518 apparently
healthy human subjects were included in the present in-
vestigation. The study underwent ethics review and ap-
proval (permit number 101-10/MSHP/CENR/P; Abidjan,
Côte d’Ivoire), and its purpose was explained to district
health authorities and villagers prior to sample collec-
tion. Following informed consent and completion of
questionnaires aimed at collecting general demographic
data and determining exposure to NHP-derived bush-
meat, samples were collected between May and October
2012 in 8 villages situated close to the boundary of the
Taï National park (Fig. 1a), an area with documented
transmission of zoonotic viruses from non-human pri-
mates to humans [19]. DNA was extracted from oral
swabs with the QIAamp blood & tissue kit and from fecal
samples with the Roboklon stool kit according to manu-
facturer’s instructions, and DNA was stored at −20 °C.
For the detection of HCMV and NHP CMVs, generic
PCRs were performed targeting either CMV glycopro-
tein B (gB; UL55) (PCR 1) or UL56 (PCR 2) coding
sequences (CDS) using two nested degenerate primer
sets. These had been designed earlier to enable
detection of both HCMV strains and HCMV-related
animal betaherpesviruses and were performed here as
described previously (see PCR 1 and PCR 2 in reference
[31]). Using these primers, several NHP CMVs and ro-
dent CMVs had been discovered previously [31, 35, 36].
Longer gB sequences of identified HCMVs were ob-
tained by applying nested non-degenerate (specific)
primers (PCR 3), with amplification products of 1.06 kb
in first round and 0.9 kb in second round. The forward
and backward primers of the first round were 5’- CGT
TACGTGACGGTCAAGGA −3’and 5’- GTGAGTAG
CAGCGTCCTGG −3’, respectively; those of the second
round 5’- GCACCTGGCTCTATCGTGAG −3’and 5’-
GCGGCAATCGGTTTGTTGTA −3’. The first round
was performed with 5μl of DNA as template, 12.7μl of
PCR mix (containing 1× AmpliTaq™ buffer, 2.0 mM
MgCl2, 5 % DMSO, dNTPs at 200 mM each, 1.0 unit of
AmpliTaq Gold Polymerase; Applied Biosystems) and 1
μM of each first-round sense and antisense primer. In
the second-round amplification, 1 μl of the first ampli-
fication product was added to 12.7 μl of PCR mix with
1μM of each second-round primer. PCR was performed
on a T-gradient S thermocycler (Biometra, Germany)
with ‘hot-start’ activation of polymerase at 95 °C for 12
min, followed by 45 cycles of denaturation (95 °C, 30s),
annealing (60 °C, 30s), and elongation (72 °C, 2min),
and final elongation at 72 °C for 10min. In addition, for
comprehensive amplification of colobus CMVs, a nested
set of non-degenerate (specific) primers (PCR 4) was used
that targets binding sites completely conserved among all
publicly available gB nucleic acid sequences of colobus
CMVs (but not HCMVs) (see PCR 4 in ref. [31]).
With PCR 1 (target: gB CDS) and PCR 2 (target: UL56
CDS) HCMV was identified in 16 oral and fecal samples
of 13 individuals (7 oral and 2 fecal samples with PCR 1; 4
oral and 3 fecal samples with PCR 2). This equates to an
overall detection rate (combined results of PCR 1 and 2)
of 2.6 % in the samples and 2.5 % (CI 1.43–4.29 %) in
the human subjects. None of the subjects was positive
in both oral and fecal samples. In BLAST analysis, the
Ivorian HCMV sequences were 99–100 % identical to
known HCMV types. Colobus CMV sequences were
not detected.
Since the amplified HCMV sequences were rather short
for conclusive comparison with published sequences, we
amplified an extended gB sequence (approximately 0.9 kb)
using PCR 3 that covers the region of highest amino acid
diversity within the gB gene, surrounding the R-X-K/R-R
recognition motif for the cellular endoprotease furin [37],
and allows to readily differentiate the detected HCMVs
from each other and from colobus CMVs. This was
successfull for 7 individuals (from villages Daobly,
Gouliako, Pauleoula, Ponan, Taï, and Zaïpobly; see Fig. 1a
and b). The sequences were deposited in GenBank under
the accession numbers KT716432- KT716438. In a nu-
cleotide alignment these sequences were all 99–100 %
identical to known HCMVs (strain Merlin, Genbank




Fig. 1 a Map of the study area in Western Côte d’Ivoire showing the sampling localities in the red circle. Villages are represented by black dots,
the boundary of Taï National park by green line, road by black line, tracks by purple lines, rivers by blue lines. b Alignment of partial glycoprotein
B amino acid (aa) sequences shown as a cartoon. Conserved aa are given in grey color; non-conserved aa are colored according to their type.
The region between aa positions 190 and 230 comprises the recognition motif for the cellular endoprotease furin. For the HCMV strains, their
cleavage site (CLS) type is indicated by numbers (CLS1-CLS5). The study sequence names are marked with a star
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accession number [acc. no.] NC006273; strain Towne, acc.
no. FJ616285; strain Toledo, acc. no. GU937742; strain
AD169, acc. no. FJ527563) (Fig. 1b). In contrast, colobus
CMV DNA was not detected in a large subset (306 oral
and 160 fecal) of the above described samples (107 oral
and 25 fecal samples were exhausted) using colobus
CMV-specific PCR 4 (CI 0.00-0.01 %), while control PCR
performed using colobus monkey samples that had been
previously determined to contain colobus CMV gen-
omic DNA [31], showed consistent detection of colobus
CMV by all PCRs (PCRs 1, 2, 4). A recent study has
shown a considerable prevalence of CMV in black-and-
white (10 %) and western red (22 %) colobus monkeys
from this geographic region [31], and the exposure rate
to colobus monkeys through hunting, slaughtering and
preparation of bushmeat around the Taï National Park
is high [29, 38]. Taking this into account, our results
suggest that colobus CMVs are not frequently transmit-
ted to humans. The results do not necessarily imply
that CMV transmission from monkeys to humans is
completely absent, but the relatively large number of
human samples collected over 8 villages suggests that if
transmission does occur, it is an extremely rare event
that does not commonly result in establishment of a
persistent infection. It is also possible that individuals
infected with colobus CMV may have remained uniden-
tified because the virus was not shed in saliva and feces
or because the applied PCRs did not possess maximum
sensitivity for detection of CMVs. Despite this, the 2.6 %
HCMV prevalence determined here in a collection of oral
and fecal swabs is well in accord with previous PCR-based
studies on healthy subjects reporting HCMV detection
rates in blood of 0–8 % of children and adults from
Uganda, Germany, Latvia, Australia and Japan [39–43]
(studies based on fecal samples were to our knowledge
not reported). In addition, sequences of other viruses have
been detected previously in the present sample set [33]
indicating absence of PCR inhibitors, and the use of
colobus-specific PCR able to identify colobus CMV in con-
trol colobus monkey samples indicates this PCR is of suffi-
cient sensitivity to detect colobus CMV present at levels
found within its natural host. Taken together, this suggests
that, if individuals were infected with colobus CMV,
absence of shedding in feces and saliva or inhibition of
PCR detection was likely not a critical confounding factor.
The likely absence of monkey-to-human cross-species
transmission in the setting investigated here and our pre-
vious finding that monkey CMVs are not transmitted to
chimpanzees [31], indicates a high level of specificity of
CMVs to their primate hosts, with absence of a capacity
for infection in closely related primate species. This sug-
gests that the potential for environmental spread of CMVs
from target to non-target host species is generally low and
that CMV, similar to other DNA viruses [44], are inable to
genetically adapt to a level sufficient to infect and then
persist within the new host. Uncharacterized protective
host mechanisms may also play a role [45], as in vitro
studies showed that species-specific CMV replicated only
poorly in cells from other species [46, 47]. Taken together,
these factors may severely limit the potential of the virus
for adaptation to a new host and the ability for cross-
species epizootic/zoonotic transmission [31].
There is a high burden of disease due to HCMV infec-
tion in newborns, non-HAART treated AIDS patients
and transplant recipients. Several vaccines are presently
under development, among them a glycoprotein B-based
vaccine [48]. HCMV strains are highly variable and
naturally acquired HCMV infection does not produce
immunity to reinfection with a different strain. There-
fore, knowledge of worldwide HCMV diversity is of
critical importance for further vaccine development.
The sequence data obtained here from people in rural
Côte d’Ivoire suggest that strain diversity does not
substantially differ from that in other parts of the
world. Determination of complete genome sequences
would be desirable to confirm this finding.
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